Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Angiogenesis
Published in: Angiogenesis 4/2010

01-12-2010 | Original Paper

Comparative analysis of angiogenic gene expression in normal and impaired wound healing in diabetic mice: effects of extracorporeal shock wave therapy

Authors: Stephen R. Zins, Mihret F. Amare, Douglas K. Tadaki, Eric. A. Elster, Thomas A. Davis

Published in: Angiogenesis | Issue 4/2010

Login to get access

Abstract

Impaired wound healing is a persistent clinical problem which has been treated with mixed results. Studies aimed at elucidating the mechanism of impaired wound healing have focused on small cohorts of genes which leave an incomplete picture of the wound healing process. We aimed to investigate impaired wound healing via a comprehensive panel of angiogenic/inflammation-related genes and wound closure kinetics with and without the application of extracorporeal shock wave therapy (ESWT), which has been demonstrated to improve wound healing. Full-thickness skin from the dorsal surface of “normal” (BALB/c) and “impaired” (db +/db +) mice was excised, and wound margin tissue was harvested 2, 7, and 10 days post injury. A separate, but identical wound model was established over 40 days in order to measure wound closure kinetics. Over time, the normal non-ESWT treated wounds exhibited varying patterns of elevated expression of 25–30 genes, whereas wounds with impaired healing displayed prolonged elevated expression of only a few genes (CXCL2, CXCL5, CSF3, MMP9, TGF-α). In response to ESWT, gene expression was augmented in both types of wounds, especially in the expression of PECAM-1; however, ESWT had no effect on wound closure in either model. In addition, multiple doses of ESWT exacerbated the delayed wound healing, and actually caused the wounds to initially increase in size. These data provide a more complete picture of impaired wound healing, and a way to evaluate various promising treatments.
Literature
1.
Werner S, Grose R (2003) Regulation of wound healing by growth factors and cytokines. Physiol Rev 83(3):835–870PubMed
2.
3.
4.
Menke NB, Ward KR, Witten TM, Bonchev DG, Diegelmann RF (2007) Impaired wound healing. Clin Dermatol 25(1):19–25CrossRefPubMed
5.
Bauer SM, Bauer RJ, Velazquez OC (2005) Angiogenesis, vasculogenesis, and induction of healing in chronic wounds. Vasc Endovascular Surg 39(4):293–306CrossRefPubMed
6.
Ochoa O, Torres FM, Shireman PK (2007) Chemokines and diabetic wound healing. Vascular 15(6):350–355PubMed
7.
Mast BA, Schultz GS (1996) Interactions of cytokines, growth factors, and proteases in acute and chronic wounds. Wound Repair Regen 4(4):411–420CrossRefPubMed
8.
Broughton G II, Janis JE, Attinger CE (2006) Wound healing: an overview. Plast Reconstr Surg 117(7 Suppl):1e-S–32e-S
9.
Mullner T, Mrkonjic L, Kwasny O, Vecsei V (1997) The use of negative pressure to promote the healing of tissue defects: a clinical trial using the vacuum sealing technique. Br J Plast Surg 50(3):194–199CrossRefPubMed
10.
Franz MG, Steed DL, Robson MC (2007) Optimizing healing of the acute wound by minimizing complications. Curr Probl Surg 44(11):691–763CrossRefPubMed
11.
Neal MS (2001) Angiogenesis: is it the key to controlling the healing process? J Wound Care 10(7):281–287PubMed
12.
Romagnani P, Lasagni L, Annunziato F, Serio M, Romagnani S (2004) CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol 25(4):201–209CrossRefPubMed
13.
Distler JH, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, Distler O (2003) Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med 47(3):149–161PubMed
14.
Callaghan MJ, Chang EI, Seiser N et al (2008) Pulsed electromagnetic fields accelerate normal and diabetic wound healing by increasing endogenous FGF-2 release. Plast Reconstr Surg 121(1):130–141CrossRefPubMed
15.
Cianfarani F, Zambruno G, Brogelli L et al (2006) Placenta growth factor in diabetic wound healing: altered expression and therapeutic potential. Am J Pathol 169(4):1167–1182CrossRefPubMed
16.
Wang CJ (2003) An overview of shock wave therapy in musculoskeletal disorders. Chang Gung Med J 26(4):220–232PubMed
17.
Yan X, Zeng B, Chai Y, Luo C, Li X (2008) Improvement of blood flow, expression of nitric oxide, and vascular endothelial growth factor by low-energy shockwave therapy in random-pattern skin flap model. Ann Plast Surg 61(6):646–653CrossRefPubMed
18.
Nishida T, Shimokawa H, Oi K et al (2004) Extracorporeal cardiac shock wave therapy markedly ameliorates ischemia-induced myocardial dysfunction in pigs in vivo. Circulation 110(19):3055–3061CrossRefPubMed
19.
Stojadinovic A, Elster EA, Anam K et al (2008) Angiogenic response to extracorporeal shock wave treatment in murine skin isografts. Angiogenesis 11(4):369–380CrossRefPubMed
20.
Aicher A, Heeschen C, Sasaki K, Urbich C, Zeiher AM, Dimmeler S (2006) Low-energy shock wave for enhancing recruitment of endothelial progenitor cells: a new modality to increase efficacy of cell therapy in chronic hind limb ischemia. Circulation 114(25):2823–2830CrossRefPubMed
21.
Meirer R, Brunner A, Deibl M, Oehlbauer M, Piza-Katzer H, Kamelger FS (2007) Shock wave therapy reduces necrotic flap zones and induces VEGF expression in animal epigastric skin flap model. J Reconstr Microsurg 23(4):231–236CrossRefPubMed
22.
Davis TA, Stojadinovic A, Anam K et al (2009) Extracorporeal shock wave therapy suppresses the early proinflammatory immune response to a severe cutaneous burn injury. Int Wound J 6(1):11–21CrossRefPubMed
23.
Kuo YR, Wang CT, Wang FS, Yang KD, Chiang YC, Wang CJ (2009) Extracorporeal shock wave treatment modulates skin fibroblast recruitment and leukocyte infiltration for enhancing extended skin-flap survival. Wound Repair Regen 17(1):80–87CrossRefPubMed
24.
Kuo YR, Wu WS, Hsieh YL et al (2007) Extracorporeal shock wave enhanced extended skin flap tissue survival via increase of topical blood perfusion and associated with suppression of tissue pro-inflammation. J Surg Res 143(2):385–392CrossRefPubMed
25.
Schaden W, Thiele R, Kolpl C et al (2007) Shock wave therapy for acute and chronic soft tissue wounds: a feasibility study. J Surg Res 143(1):1–12CrossRefPubMed
26.
Ennis WJ, Lee C, Meneses P (2007) A biochemical approach to wound healing through the use of modalities. Clin Dermatol 25(1):63–72CrossRefPubMed
27.
Ingber DE (2006) Cellular mechanotransduction: putting all the pieces together again. Faseb J 20(7):811–827CrossRefPubMed
28.
Kavros SJ, Liedl DA, Boon AJ, Miller JL, Hobbs JA, Andrews KL (2008) Expedited wound healing with noncontact, low-frequency ultrasound therapy in chronic wounds: a retrospective analysis. Adv Skin Wound Care 21(9):416–423CrossRefPubMed
29.
Walker NA, Denegar CR, Preische J (2007) Low-intensity pulsed ultrasound and pulsed electromagnetic field in the treatment of tibial fractures: a systematic review. J Athl Train 42(4):530–535PubMed
30.
Kavros SJ, Miller JL, Hanna SW (2007) Treatment of ischemic wounds with noncontact, low-frequency ultrasound: the Mayo clinic experience, 2004–2006. Adv Skin Wound Care 20(4):221–226CrossRefPubMed
31.
Fukumoto Y, Ito A, Uwatoku T et al (2006) Extracorporeal cardiac shock wave therapy ameliorates myocardial ischemia in patients with severe coronary artery disease. Coron Artery Dis 17(1):63–70CrossRefPubMed
32.
Rompe JD, Zoellner J, Nafe B (2001) Shock wave therapy versus conventional surgery in the treatment of calcifying tendinitis of the shoulder. Clin Orthop Relat Res 387:72–82CrossRefPubMed
33.
Kikuchi Y, Ito K, Ito Y et al (2010) Double-blind and placebo-controlled study of the effectiveness and safety of extracorporeal cardiac shock wave therapy for severe angina pectoris. Circ J 74(3):589–591CrossRefPubMed
34.
Schaden W, Fischer A, Sailler A (2001) Extracorporeal shock wave therapy of nonunion or delayed osseous union. Clin Orthop Relat Res 387:90–94CrossRefPubMed
35.
Belperio JA, Keane MP, Arenberg DA et al (2000) CXC chemokines in angiogenesis. J Leukoc Biol 68(1):1–8PubMed
36.
Rosenthal A, Lindquist PB, Bringman TS, Goeddel DV, Derynck R (1986) Expression in rat fibroblasts of a human transforming growth factor-alpha cDNA results in transformation. Cell 46(2):301–309CrossRefPubMed
37.
Schreiber AB, Winkler ME, Derynck R (1986) Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science 232(4755):1250–1253CrossRefPubMed
38.
Antoniades HN, Galanopoulos T, Neville-Golden J, Kiritsy CP, Lynch SE (1993) Expression of growth factor and receptor mRNAs in skin epithelial cells following acute cutaneous injury. Am J Pathol 142(4):1099–1110PubMed
39.
Luetteke NC, Qiu TH, Peiffer RL, Oliver P, Smithies O, Lee DC (1993) TGF alpha deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice. Cell 73(2):263–278CrossRefPubMed
40.
Mann GB, Fowler KJ, Gabriel A, Nice EC, Williams RL, Dunn AR (1993) Mice with a null mutation of the TGF alpha gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation. Cell 73(2):249–261CrossRefPubMed
41.
DeLisser HM, Christofidou-Solomidou M, Strieter RM et al (1997) Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol 151(3):671–677PubMed
42.
Fujiwara K (2006) Platelet endothelial cell adhesion molecule-1 and mechanotransduction in vascular endothelial cells. J Intern Med 259(4):373–380CrossRefPubMed
43.
Li S, Huang NF, Hsu S (2005) Mechanotransduction in endothelial cell migration. J Cell Biochem 96(6):1110–1126CrossRefPubMed
44.
Greene AK, Puder M, Roy R et al (2006) Microdeformational wound therapy: effects on angiogenesis and matrix metalloproteinases in chronic wounds of 3 debilitated patients. Ann Plast Surg 56(4):418–422CrossRefPubMed
45.
Saxena V, Hwang CW, Huang S, Eichbaum Q, Ingber D, Orgill DP (2004) Vacuum-assisted closure: microdeformations of wounds and cell proliferation. Plast Reconstr Surg 114(5):1086–1096 (discussion 1097–1088)CrossRefPubMed
46.
Parks WC, Wilson CL, Lopez-Boado YS (2004) Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 4(8):617–629CrossRefPubMed
47.
McCawley LJ, O’Brien P, Hudson LG (1998) Epidermal growth factor (EGF)- and scatter factor/hepatocyte growth factor (SF/HGF)- mediated keratinocyte migration is coincident with induction of matrix metalloproteinase (MMP)-9. J Cell Physiol 176(2):255–265CrossRefPubMed
48.
Sawicki G, Marcoux Y, Sarkhosh K, Tredget EE, Ghahary A (2005) Interaction of keratinocytes and fibroblasts modulates the expression of matrix metalloproteinases-2 and -9 and their inhibitors. Mol Cell Biochem 269(1–2):209–216CrossRefPubMed
49.
Van Den Steen PE, Wuyts A, Husson SJ, Proost P, Van Damme J, Opdenakker G (2003) Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities. Eur J Biochem 270(18):3739–3749CrossRef
50.
Wall SJ, Bevan D, Thomas DW, Harding KG, Edwards DR, Murphy G (2002) Differential expression of matrix metalloproteinases during impaired wound healing of the diabetes mouse. J Invest Dermatol 119(1):91–98CrossRefPubMed
51.
Yager DR, Zhang LY, Liang HX, Diegelmann RF, Cohen IK (1996) Wound fluids from human pressure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wound fluids. J Invest Dermatol 107(5):743–748CrossRefPubMed
52.
Wysocki AB, Staiano-Coico L, Grinnell F (1993) Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol 101(1):64–68CrossRefPubMed
53.
Cao R, Brakenhielm E, Pawliuk R et al (2003) Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 9(5):604–613CrossRefPubMed
54.
Miller DL, Ortega S, Bashayan O, Basch R, Basilico C (2000) Compensation by fibroblast growth factor 1 (FGF1) does not account for the mild phenotypic defects observed in FGF2 null mice. Mol Cell Biol 20(6):2260–2268CrossRefPubMed
55.
Aggarwal VS, Liao J, Bondarev A et al (2006) Dissection of Tbx1 and Fgf interactions in mouse models of 22q11DS suggests functional redundancy. Hum Mol Genet 15(21):3219–3228CrossRefPubMed
56.
Mitsiadis TA, Tucker AS, De Bari C, Cobourne MT, Rice DP (2008) A regulatory relationship between Tbx1 and FGF signaling during tooth morphogenesis and ameloblast lineage determination. Dev Biol 320(1):39–48CrossRefPubMed
57.
Lania G, Zhang Z, Huynh T et al (2009) Early thyroid development requires a Tbx1-Fgf8 pathway. Dev Biol 328(1):109–117CrossRefPubMed
58.
Terasaki K, Kanzaki T, Aoki T, Iwata K, Saiki I (2003) Effects of recombinant human tissue inhibitor of metalloproteinases-2 (rh-TIMP-2) on migration of epidermal keratinocytes in vitro and wound healing in vivo. J Dermatol 30(3):165–172PubMed
59.
Kzhyshkowska J, Workman G, Cardo-Vila M et al (2006) Novel function of alternatively activated macrophages: stabilin-1-mediated clearance of SPARC. J Immunol 176(10):5825–5832PubMed
60.
Apte RS, Barreiro RA, Duh E, Volpert O, Ferguson TA (2004) Stimulation of neovascularization by the anti-angiogenic factor PEDF. Invest Ophthalmol Vis Sci 45(12):4491–4497CrossRefPubMed
61.
Kampfer H, Brautigam L, Geisslinger G, Pfeilschifter J, Frank S (2003) Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair. J Invest Dermatol 120(5):880–890CrossRefPubMed
62.
Kampfer H, Schmidt R, Geisslinger G, Pfeilschifter J, Frank S (2005) Wound inflammation in diabetic ob/ob mice: functional coupling of prostaglandin biosynthesis to cyclooxygenase-1 activity in diabetes-impaired wound healing. Diabetes 54(5):1543–1551CrossRefPubMed
63.
Streit M, Velasco P, Riccardi L et al (2000) Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice. EMBO J 19(13):3272–3282CrossRefPubMed
64.
Italiano JE Jr, Richardson JL, Patel-Hett S et al (2008) Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 111(3):1227–1233CrossRefPubMed
Metadata
Title
Comparative analysis of angiogenic gene expression in normal and impaired wound healing in diabetic mice: effects of extracorporeal shock wave therapy
Authors
Stephen R. Zins
Mihret F. Amare
Douglas K. Tadaki
Eric. A. Elster
Thomas A. Davis
Publication date
01-12-2010
Publisher
Springer Netherlands
Published in
Angiogenesis / Issue 4/2010
Print ISSN: 0969-6970
Electronic ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-010-9186-9

Other articles of this Issue 4/2010

Angiogenesis 4/2010 Go to the issue

Original Paper

Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture

Original Paper

Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model

Original Paper

Vascular regrowth following photodynamic therapy in the chicken embryo chorioallantoic membrane

Original Paper

The impact of EPLINα (Epithelial protein lost in neoplasm) on endothelial cells, angiogenesis and tumorigenesis

Original Paper

Targeting NF-κB in infantile hemangioma-derived stem cells reduces VEGF-A expression
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits